Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trebananib + trastuzumab
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
AMG 386 + trastuzumab is a combination therapy evaluated in the neoadjuvant setting for high-risk, early-stage breast cancer. AMG 386 (trebananib) is a recombinant peptibody (peptide-Fc fusion protein) that acts as an angiogenesis inhibitor by binding to and neutralizing angiopoietin-1 and angiopoietin-2, thereby preventing their interaction with the Tie2 receptor. Trastuzumab is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). This combination was specifically studied in the I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2) platform trial to assess whether adding an anti-angiogenic agent to HER2-targeted therapy and standard chemotherapy improves pathological complete response (pCR) rates in HER2-positive breast cancer patients. While the combination completed Phase 2 testing within the I-SPY 2 framework, it did not proceed to Phase 3 for this specific indication.
- Other names
- trebananib + trastuzumab
02
Targets
ANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trebananib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trebananib + trastuzumab.